Business Wire

Quectel Unveils Industry-First Quad-Band GNSS Module, Expanding Comprehensive GNSS Solutions Portfolio

25.7.2024 12:21:00 EEST | Business Wire | Press release

Share

Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce the LG290P, the first quad-band GNSS module, designed to deliver high performance for the most demanding applications, ensuring exceptional RTK availability and quality even in challenging environments. Providing the instantaneous centimeter-level accuracy needed to ensure the precision required for applications such as precision agriculture, robotic lawn mowers, surveying and personal robots, the module also delivers superior coverage that supports base stations from greater distances, ensuring reliable performance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725061807/en/

Quectel unveils industry-first quad-band GNSS module, expanding comprehensive GNSS solutions portfolio (Photo: Business Wire)

The introduction of the LG290P module expands Quectel's range of high-accuracy, RTK-capable GNSS modules. This range includes the dual-band industrial-grade LC29H, the automotive-grade LG69T, and now the quad-band LG290P, providing users with a selection of GNSS modules to cover a wide variety of applications.

Future-proofing applications by supporting all constellations including GPS, GLONASS, Galileo, BDS, NavIC, QZSS, as well as SBAS support (WASS, EGNOS, MSAS, and GAGAN) and advanced satellite-based signals such as PPP-B2b, CLAS (QZSS L6), Galileo HAS E6, the LG290P is a cost-effective industrial-grade module that receives L1, L2, L5 and E6 frequency bands.

In addition, the LG290P is compatible with Quectel triple band RTK Services and ensures superior coverage that supports base stations from greater distances, ensuring stable and reliable performance in the most difficult urban environments, making it exceptionally well suited for sectors such as autonomous lawnmowers, delivery robots, surveying and precision agriculture. The quad-band solution can enhance the RTK fix rate by 50% compared to dual band in extremely challenging environments, such as a garden encircled by trees and walls. Additionally, it can reduce the time to achieve RTK fix to less than five seconds, in contrast to the ten to fifteen seconds required by the dual band solution.

“Introducing the quad-band GNSS Module to the market represents our commitment to advancing technology and providing our customers with the most reliable and accurate navigation solutions available,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “We believe this product will be a game-changer in many fields, enabling new possibilities and improving efficiencies and precise location.”

The module supports an advanced multi-frequency RTK algorithm, ensuring rapid and reliable RTK high-precision positioning results even in challenging conditions such as under dense tree cover, alongside buildings or inside urban canyons. With advanced anti-interference technology, the LG290P incorporates a professional-grade interference signal detection and Narrowband Interference Canceller (NIC), significantly enhancing signal reception performance in complex electromagnetic environments. Moreover, supporting integrity monitoring and authentication information verification, the LG290P aids automatic navigation systems in making control decisions, particularly fitting for critical applications like autonomous vehicles and lawnmowers.

The LG290P excels in terms of security by incorporating on-chip ECC check and Secure Boot for firmware protection. Measuring a compact 12.2 mm × 16.0 mm × 2.6 mm, the LG290P is the smallest quad-band module available, offering greater design flexibility for customers, reducing integration challenges, and enabling compact designs for a wide array of precision products.

Customers are also able to streamline their design process by sourcing the appropriate antenna for this module, ensuring flexibility and compatibility for diverse project requirements.

The LG290P quad band GNSS module is now available to order through the Quectel website and distributors.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,600 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240725061807/en/

Contacts

Media: media@quectel.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye